Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)

Biochemical and Biophysical Research Communications

Volumn 397, Issue 1, 2010, Pages 27-33

  Oliveras Ferraros, Cristina ^a,b   Vazquez Martin, Alejandro ^a,b   Martin Castillo, Begoña ^a,b   Cufí, Silvia ^a,b   Barco, Sonia Del ^a,b   Lopez Bonet, Eugeni ^c   Brunet, Joan ^a,b   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Basal like; Breast cancer; HER2; Stem cells; Trastuzumab

Indexed keywords

CD24 ANTIGEN; CHEMOKINE; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; HERMES ANTIGEN; LYMPHOCYTE SURFACE MARKER; METALLOPROTEINASE; PLASTIC; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE TARGETING; GENETIC RESISTANCE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MESODERM; NEOPLASTIC STEM CELLS;

EID: 77953651764     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.041     Document Type: Article

References (50)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235 (1987) 177-182
2. Hynes N.E., and Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198 (1994) 165-184
3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 (2001) 1-13
4. Pegram M.D., Konecny G., and Slamon D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res. 103 (2000) 57-75
5. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289
6. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., and Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14 (1996) 737-744
7. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., and Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17 (1999) 2639-2648
8. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
9. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. N. Engl. J. Med. 353 (2005) 1673-1684
10. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Láng I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Rüschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., and Gelber R.D. Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
11. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353 (2005) 1734-1736
12. Gonzalez-Angulo A.M., Hortobágyi G.N., and Esteva F.J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11 (2006) 857-867
13. Nahta R., and Esteva F.J. HER-2-targeted therapy: lessons learned and future directions. Clin. Cancer Res. 9 (2003) 5078-5084
14. Nahta R., and Esteva F.J. Hercept. mechanisms of action and resistance. Cancer Lett. 232 (2006) 123-138
15. Nahta [15] R., Yu D., Hung M.C., Hortobagyi G.N., and Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3 (2006) 269-280
16. Nahta R., and Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8 (2006) 215
17. Vazquez-Martin A., Oliveras-Ferraros C., and Menendez J.A. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One. 4 (2009) e6251
18. Chen F.L., Xia W., and Spector N.L. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 14 (2008) 6730-6734
19. Spector N.L., and Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27 (2009) 5838-5847
20. Esteva F.J., Yu D., Hung M.C., and Hortobagyi G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7 (2010) 98-107
21. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., and Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20 (2002) 719-726
22. Valabrega G., Montemurro F., and Aglietta M. Trastuzumab: mechanism of action resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18 (2007) 977-984
23. Tanner M., Kapanen A.I., Junttila T., Raheem O., Grenman S., Elo J., Elenius K., and Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther. 3 (2004) 1585-1592
24. Nagy P., Friedländer E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., and Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65 (2005) 473-482
25. Pályi-Krekk Z., Barok M., Isola J., Tammi M., Szöllosi J., and Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur. J. Cancer 43 (2007) 2423-2433
26. Jönsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P., Oredsson S., Ringnér M., Höglund M., and Borg A. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46 (2007) 543-558
27. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988
28. Korkaya H., Paulson A., Iovino F., and Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27 (2008) 6120-6230
29. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007) 555-567
30. Bedard P.L., Cardoso F., and Piccart-Gebhart M.J. Stemming resistance to HER-2 targeted therapy. J. Mammary Gland Biol. Neoplasia 14 (2009) 55-66
31. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., and Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100 (2008) 672-679
32. Magnifico A., Albano L., Campaner S., Delia D., Castiglioni F., Gasparini P., Sozzi G., Fontanella E., Menard S., and Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 15 (2009) 2010-2021
33. Sheridan C., Kishimoto H., Fuchs R.K., Mehrotra S., Bhat-Nakshatri P., Turner C.H., Goulet Jr. R., Badve S., and Nakshatri H. CD44α breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 8 (2006) R59
34. Honeth G., Bendahl P.O., Ringnér M., Saal L.H., Gruvberger-Saal S.K., Lövgren K., Grabau D., Fernö M., Borg A., and Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10 (2008) R53
35. Grimshaw M.J., Cooper L., Papazisis K., Coleman J.A., Bohnenkamp H.R., Chiapero-Stanke L., Taylor-Papadimitriou J., and Burchell J.M. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 10 (2008) R52
36. Fillmore C.M., and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10 (2008) R25
37. Nakshatri H., Srour E.F., and Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. 4 (2009) 50-60
38. Bauerschmitz G.J., Ranki T., Kangasniemi L., Ribacka C., Eriksson M., Porten M., Herrmann I., Ristimäki A., Virkkunen P., Tarkkanen M., Hakkarainen T., Kanerva A., Rein D., Pesonen S., and Hemminki A. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res. 68 (2008) 5533-5539
39. K. Rennstam, N. McMichael, P. Berglund, G. Honeth, C. Hegardt, L. Rydén, L. Luts, P. O. Bendahl, I. Hedenfalk, Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer, Breast Cancer Res. Treat. 2009 Oct 1. [Epub ahead of print].
40. Piccart M. Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin. Breast Cancer 8 (2008) S100-S113
41. Rennstam K., Jönsson G., Tanner M., Bendahl P.O., Staaf J., Kapanen A.I., Karhu R., Baldetorp B., Borg A., and Isola J. Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet. 172 (2007) 95-106
42. Barok M., Isola J., Pályi-Krekk Z., Nagy P., Juhász I., Vereb G., Kauraniemi P., Kapanen A., Tanner M., Vereb G., and Szöllösi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6 (2007) 2065-2072
43. K. Köninki, M. Barok, M. Tanner, S. Staff, J. Pitkänen, P. Hemmilä, J. Ilvesaro, J Isola, Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells, Cancer Lett. 2010 Feb 27. [Epub ahead of print].
44. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., and Hung M.C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6 (2004) 459-469
45. DiGiovanna M.P., Chu P., Davison T.L., Howe C.L., Carter D., Claus E.B., and Stern D.F. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 62 (2002) 667-6673
46. Alexe G., Dalgin G.S., Scanfeld D., Tamayo P., Mesirov J.P., DeLisi C., Harris L., Barnard N., Martel M., Levine A.J., Ganesan S., and Bhanot G. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 67 (2007) 10669-10676
47. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., and Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008) 704-715
48. Kalluri R., and Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119 (2009) 1420-1428
49. Ostler J., Jones S., Zhao W., Yearsley K., Ye Y., and Barsky S. Resistance to Her-2/neu targeting in human breast cancer may be mediated by epithelial-mesenchymal transition. Proc. Amer. Assoc. Cancer Res. 127 (2008)
50. Sarrió D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., and Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68 (2008) 989-997